SCHEMBL10331302

SCHEMBL10331302

COc1cc2[nH]c(=O)c(C(=O)Nc3cc(C(=O)NCc4cccs4)ccc3Cl)cc2cn1

nearest known ligand 0.77

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 20/20 0.77
▸ DYRK1B Q9Y463 19/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10331282 0.92 DYRK1A (0.64) DYRK1ADYRK1B
SCHEMBL10331185 0.87 DYRK1A (0.75) DYRK1ADYRK1B
SCHEMBL10446985 0.87 DYRK1A (1.00) DYRK1ADYRK1B
SCHEMBL10331284 0.87 DYRK1A (0.63) DYRK1ADYRK1B
SCHEMBL10331379 0.86 DYRK1A (0.77) DYRK1ADYRK1B
SCHEMBL10331264 0.86 DYRK1A (0.66) DYRK1ADYRK1B
SCHEMBL10331303 0.85 DYRK1A (0.76) DYRK1ADYRK1B
SCHEMBL10321533 0.83 DYRK1A (0.63) DYRK1ADYRK1B
SCHEMBL10322245 0.83 DYRK1A (0.72) DYRK1ADYRK1B
SCHEMBL10331210 0.81 DYRK1A (0.55) DYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO claimed
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES PSEN1, BRCA1, PSEN2 DYRK1A 1366/4885DYRK1B 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback